Leonardo DRS, Inc. DRS 深 滬
已收盤 08-08 16:00:00 美东时间
41.49
+0.240
+0.58%
華盛通- 最 高41.74
- 今 開41.32
- 成交量 117.72万股
- 最 低 40.77
- 昨 收 41.25
- 總市值 110.36亿
- 52周最高 49.31
- 市盈率 靜 52.14
- 換手率 0.44%
- 52周最低 25.82
- 委 比 88.38%
- 總股本 2.66亿
- 歷史最高 49.31
- 量 比 0.87
- 振 幅 2.35%
- 歷史最低 8.93
- 每 手 1
- 風險率 6.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Industrials Stocks Moving In Tuesday's After-Market Session
Gainers Orion Energy Sys (NASDAQ:OESX) shares rose 11.2% to $0.63 during Tuesd...
08-06 05:07
Morgan Stanley Maintains Equal-Weight on Leonardo DRS, Raises Price Target to $47
Morgan Stanley analyst Kristine Liwag maintains Leonardo DRS (NASDAQ:DRS) with a Equal-Weight and raises the price target from $44 to $47.
07-31 23:31
Leonardo DRS shares are trading lower. The company reported Q2 financial results.
Leonardo DRS shares are trading lower. The company reported Q2 financial result...
07-31 01:39
Leonardo DRS declares $0.09 dividend
Leonardo DRS (NASDAQ:DRS) declares $0.09/share quarterly dividend, in line with previous. Forward yield 0.78% Payable Sept. 23; for shareholders of record Aug. 20; ex-div Aug. 20. See DRS Dividend Sc...
07-30 22:05
Leonardo DRS Raises FY2025 Adj EPS Guidance from $1.02-$1.08 to $1.06-$1.11 vs $1.08 Est; Raises FY2025 Sales Guidance from $3.425B-$3.525B to $3.525B-$3.600B vs $3.521B Est
Leonardo DRS (NASDAQ:DRS) raises FY2025 Adj EPS guidance from $1.02-$1.08 to $1.06-$1.11 vs $1.08 analyst estimate. Raises FY2025 sales outlook from $3.425 billion-$3.525 billion to $3.525 billion-$3.600 billion vs
07-30 19:32
Insights Ahead: Leonardo DRS's Quarterly Earnings
Leonardo DRS (NASDAQ:DRS) is set to give its latest quarterly earnings report o...
07-30 01:01
SA Asks: Which stocks could benefit from the Golden Dome project?
Which stocks could benefit from the Trump administration's proposed multi-billion dollar Golden Dome defense project? We asked Seeking Alpha analysts Leo Nelissen, Dhierin Bechai and Cappuccino Financ...
07-28 02:00
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review
Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess its development strategy.
07-19 02:17
强生(JNJ.US)突破性疗法获优先审评资格 超80%患者肿瘤完全消失
今日，强生(JNJ.US)宣布，美国FDA已授予其创新膀胱内药物释放系统TAR-200新药申请(NDA)优先审评资格，用于治疗对卡介苗(BCG)无应答的高危非肌层浸润性膀胱癌(HR-NMIBC)伴原位瘤患者。
07-18 07:58
